Marco Turiah Gama

Mr. Marco Turiah Gama

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 December 2022 in Genes
Verified
Journal Article
Open access
PDF file
AMAlanne Rayssa Da Silva Melo
Alanne Rayssa Da Silva Melo
Larissa Silva de MacêdoLarissa Silva de Macêdo
Larissa Silva de Macêdo
MIMaria da Conceição Viana Invenção
Maria da Conceição Viana Invenção
Ingrid Andrêssa de MouraIngrid Andrêssa de Moura
Ingrid Andrêssa de Moura
MGMarco Turiah Gama
Marco Turiah Gama
Antonio Carlos de FreitasAntonio Carlos de Freitas
Antonio Carlos de Freitas
Gene immunization comprises mRNA and DNA vaccines, which stand out due to their simple design, maintenance, and high efficacy. Several studies indicate promising results in preclinical and clinical trials regarding immunization against ebola, human immunodeficiency virus (HIV), influenza, and human papillomavirus (HPV). The efficiency of nucleic acid vaccines has been highlighted in the fight against COVID-19 with unprecedented approval of their use in humans. However, their low intrinsic immunogenicity points to the need to use strategies capable of overcoming this characteristic and increasing the efficiency of vaccine campaigns. These strategies include the improvement of the epitopes’ presentation to the system via MHC, the evaluation of immunodominant epitopes with high coverage against emerging viral subtypes, the use of adjuvants that enhance immunogenicity, and the increase in the efficiency of vaccine transfection. In this review, we provide updates regarding some characteristics, construction, and improvement of such vaccines, especially about the production of synthetic multi-epitope genes, widely employed in the current gene-based vaccines.

11 August 2023 in Vaccines
Verified
Journal Article
Open access
PDF file
ASAnna Jéssica Duarte Silva
Anna Jéssica Duarte Silva
Ingrid Andrêssa de MouraIngrid Andrêssa de Moura
Ingrid Andrêssa de Moura
MGMarco Turiah Gama
Marco Turiah Gama
LLLígia Rosa Sales Leal
Lígia Rosa Sales Leal
SPSamara Sousa de Pinho
Samara Sousa de Pinho
Antonio Carlos de FreitasAntonio Carlos de Freitas
Antonio Carlos de Freitas
The understanding of the relationship between immunological responses and cancers, especially those related to HPV, has allowed for the study and development of therapeutic vaccines against these neoplasias. There is a growing number of studies about the composition and influence of the tumor microenvironment (TME) in the progression or establishment of the most varied types of cancer. Hence, it has been possible to structure immunotherapy approaches based on therapeutic vaccines that are even more specific and directed to components of TME and the immune response associated with tumors. Among these components are dendritic cells (DCs), which are the main professional antigen-presenting cells (APCs) already studied in therapy strategies for HPV-related cancers. On the other hand, tumor-associated macrophages are also potential targets since the profile present in tumor infiltrates, M1 or M2, influences the prognosis of some types of cancer. These two cell types can be targets for therapy or immunomodulation. In this context, our review aims to provide an overview of immunotherapy strategies for HPV-positive tumors, such as cervical and head and neck cancers, pointing to TME immune cells as promising targets for these approaches. This review also explores the potential of immunotherapy in cancer treatment, including checkpoint inhibitors, cytokine immunotherapies, immunotherapy vaccines, and cell therapies. Furthermore, it highlights the importance of understanding the TME and its effect on the design and achievement of immunotherapeutic methods.

7 August 2023 in Vaccines
Verified
Journal Article
Open access
PDF file
ASAnna Jéssica Duarte Silva
Anna Jéssica Duarte Silva
MSMylenna Máyra Gois de Sousa
Mylenna Máyra Gois de Sousa
Larissa Silva de MacêdoLarissa Silva de Macêdo
Larissa Silva de Macêdo
PNPedro Luiz de França Neto
Pedro Luiz de França Neto
Ingrid Andrêssa de MouraIngrid Andrêssa de Moura
Ingrid Andrêssa de Moura
Antonio Carlos de FreitasAntonio Carlos de Freitas
Antonio Carlos de Freitas
In the last decades, technological advances for RNA manipulation enabled and expanded its application in vaccine development. This approach comprises synthetic single-stranded mRNA molecules that direct the translation of the antigen responsible for activating the desired immune response. The success of RNA vaccines depends on the delivery vehicle. Among the systems, yeasts emerge as a new approach, already employed to deliver protein antigens, with efficacy demonstrated through preclinical and clinical trials. β-glucans and mannans in their walls are responsible for the adjuvant property of this system. Yeast β-glucan capsules, microparticles, and nanoparticles can modulate immune responses and have a high capacity to carry nucleic acids, with bioavailability upon oral immunization and targeting to receptors present in antigen-presenting cells (APCs). In addition, yeasts are suitable vehicles for the protection and specific delivery of therapeutic vaccines based on RNAi. Compared to protein antigens, the use of yeast for DNA or RNA vaccine delivery is less established and has fewer studies, most of them in the preclinical phase. Here, we present an overview of the attributes of yeast or its derivatives for the delivery of RNA-based vaccines, discussing the current challenges and prospects of this promising strategy.

15 February 2024 in ADMET and DMPK
Verified
Journal Article
Open access
PDF file
Larissa Silva de MacêdoLarissa Silva de Macêdo
Larissa Silva de Macêdo
SPSamara Sousa de Pinho
Samara Sousa de Pinho
ASAnna Jéssica Duarte Silva
Anna Jéssica Duarte Silva
Ingrid Andrêssa de MouraIngrid Andrêssa de Moura
Ingrid Andrêssa de Moura
BEBenigno Cristofer Flores Espinoza
Benigno Cristofer Flores Espinoza
Antonio Carlos de FreitasAntonio Carlos de Freitas
Antonio Carlos de Freitas
Background and purpose: The employment of yeasts for biomedical purposes has become increasingly frequent for the delivery of prophylactic and therapeutic products. Its structural components, such as β-glucans, mannan, and chitin, can be explored as immunostimulators that show safety and low toxicity. Besides, this system minimizes antigen degradation after administration, facilitating the delivery to the target cells. Review approach: This review sought to present molecules derived from yeast, called yeast shells (YS), and their applications as carrier vehicles for drugs, proteins, and nucleic acids for immunotherapy purposes. Furthermore, due to the diversity of information regarding the production and immunostimulation of these compounds, a survey of the protocols and immune response profiles generated was presented. Key results: The use of YS has allowed the development of strategies that combine efficiency and effectiveness in antigen delivery. The capsular structure can be recognized and phagocytized by dendritic cells and macrophages. In addition, the combination with different molecules, such as nanoparticles or even additional adjuvants, improves the cargo loading, enhancing the system. Activation by specific immune pathways can also be achieved by different administration routes. Conclusion: Yeast derivatives combined in different ways can increase immunostimulation, enhancing the delivery of medicines and vaccine antigens. These aspects, combined with the simplicity of the production steps, make these strategies more accessible to be applied in the prevention and treatment of various diseases.

18 December 2024 in Vaccines
Verified
Journal Article
Open access
PDF file
SPSamara Sousa de Pinho
Samara Sousa de Pinho
MIMaria da Conceição Viana Invenção
Maria da Conceição Viana Invenção
ASAnna Jéssica Duarte Silva
Anna Jéssica Duarte Silva
Larissa Silva de MacêdoLarissa Silva de Macêdo
Larissa Silva de Macêdo
BEBenigno Cristofer Flores Espinoza
Benigno Cristofer Flores Espinoza
Antonio Carlos de FreitasAntonio Carlos de Freitas
Antonio Carlos de Freitas
Background/Objectives: DNA vaccines are rapidly produced and adaptable to different pathogens, but they face considerable challenges regarding stability and delivery to the cellular target. Thus, effective delivery methods are essential for the success of these vaccines. Here, we evaluated the efficacy of capsules derived from the cell wall of the yeast Pichia pastoris as a delivery system for DNA vaccines. Methods: The capsules were extracted from the yeast Pichia pastoris strain GS115, previously grown in a YPD medium. pVAX1 expression vector was adopted to evaluate the DNA vaccine insertion and delivery. Three encapsulation protocols were tested to identify the most effective in internalizing the plasmid. The presence of plasmids inside the capsules was confirmed by fluorescence microscopy, and the encapsulation efficiency was calculated by the difference between the initial concentration of DNA used for insertion and the concentration of unencapsulated DNA contained in the supernatant. The capsules were subjected to different temperatures to evaluate their thermostability and were co-cultured with macrophages for phagocytosis analysis. HEK-293T cells were adopted to assess the cytotoxicity levels by MTT assay. Results: The microscopy results indicated that the macrophages successfully phagocytosed the capsules. Among the protocols tested for encapsulation, the one with 2% polyethylenimine for internalization showed the highest efficiency, with an encapsulation rate above 80%. However, the vaccine capsules obtained with the protocol that used 5% NaCl showed better thermal stability and encapsulation efficiency above 63% without induction of cell viability loss in HEK 293T. Conclusions: We successfully described a vaccine delivery system using yeast capsules derived from Pichia pastoris, demonstrating its potential for DNA vaccine delivery for the first time. Additional studies will be needed to characterize and improve this delivery strategy.

26 April 2023 in Preprints.org
Verified
Preprint
Open access
PDF file
ASAnna Jéssica Duarte Silva
Anna Jéssica Duarte Silva
MSMylenna Máyra Gois Souza
Mylenna Máyra Gois Souza
Larissa Silva de MacêdoLarissa Silva de Macêdo
Larissa Silva de Macêdo
PNPedro Luiz França Neto
Pedro Luiz França Neto
Ingrid Andrêssa de MouraIngrid Andrêssa de Moura
Ingrid Andrêssa de Moura
Antonio Carlos de FreitasAntonio Carlos de Freitas
Antonio Carlos de Freitas
In the last decades, technological advances related to RNA manipulation enabled and expanded its application in vaccine development. This approach comprises synthetic single-stranded mRNA molecules that direct the translation of the antigen responsible for activating the desired immune response. The success of RNA vaccines depends on the delivery vehicle employed. Among the systems, yeasts emerge as a new approach to a natural delivery platform. The presence of β-glucans and mannans in its wall is responsible for the adjuvant action of this system. Yeasts are already employed to deliver protein antigens, with success and efficacy demonstrated through pre-clinical and clinical trials. Yeast β-glucan capsules, microparticles, and nanoparticles are capable of modulating host immune responses and have a high capacity to carry RNA and small molecules, with bioavailability upon oral immunization and with targeting to receptors present in anti-gen-presenting cells (APCs). Besides, yeasts are interesting vehicles for the protection and specific delivery of therapeutic vaccines based on shRNA or dsRNA. In this review, we present an overview of the attributes of yeast or its derivatives for the delivery of RNA-based vaccines, discussing their current challenges and prospects for using this promising strategy.